Overview

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Status:
Withdrawn

Trial end date:
2010-11-01

Target enrollment:
0

Participant gender:
All

Summary

Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments. There are no clinical studies of use of Bimatoprost in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues; hence, the investigators decided to use it in treatment of localized vitiligo.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Gian Sagar Medical College and Hospital

Treatments:

Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions

Criteria

Inclusion Criteria:

1. Patient of either sex and at least 10 years old

2. Have a diagnosis of vitiligo with no news lesions or growth of old lesions in the past
6 months

3. Be able to understand the requirements of the study, the risks involved, and be able
to sign the informed consent form

4. Agree to follow and undergo all study-related procedures

Exclusion Criteria:

1. Patients showing evidence of spontaneous repigmentation in any of the lesions

2. Patients with rapidly progressive disease were also excluded.

3. Patients with hypersensitivity to the drug or any of its constituents

4. Patients with BSA > 5%